Ágota Barabássy

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

György Németh, I. Laszlovszky, Pál Czobor et al. · The Lancet · 2017 · 336 citations

Predominant Negative Symptoms, Psychiatry, Psychotic Disorder +8

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder

Eduard Vieta, Willie Earley, Maria Victoria Burgess et al. · International Clinical Psychopharmacology · 2018 · 187 citations · Full text

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors

Wolfgang Fleischhacker, Silvana Galderisi, I. Laszlovszky et al. · European Psychiatry · 2019 · 114 citations · Full text

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data

Willie Earley, Hua Guo, David G. Daniel et al. · Schizophrenia Research · 2018 · 65 citations · Full text

Acute Schizophrenia, Psychiatric Evaluation, Psychotropic Medication +18

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia

Stefan Leucht, Ágota Barabássy, I. Laszlovszky et al. · Neuropsychopharmacology · 2019 · 49 citations · Full text